Nuveen
AURA icon

Nuveen’s Aura Biosciences AURA Stock Holding History

Nuveen’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$595K Buy
83,804
+11,092
+15% +$79.4K ﹤0.01% 3189
2026
Q1 		$486K Buy
72,712
+378
+0.5% +$2.17K ﹤0.01% 2848
2025
Q4 		$394K Hold
72,334
– – ﹤0.01% 2966
2025
Q3 		$447K Hold
72,334
– – ﹤0.01% 2936
2025
Q2 		$453K Sell
72,334
-23,372
-24% -$137K ﹤0.01% 2921
2025
Q1 		$561K Hold
95,706
– – ﹤0.01% 2866
2024
Q4 		$787K Hold
95,706
– – ﹤0.01% 2808
2024
Q3 		$853K Sell
95,706
-32,240
-25% -$276K ﹤0.01% 2823
2024
Q2 		$967K Buy
127,946
+57,697
+82% +$423K ﹤0.01% 2741
2024
Q1 		$551K Hold
70,249
– – ﹤0.01% 2945
2023
Q4 		$622K Buy
70,249
+10,134
+17% +$85.8K ﹤0.01% 2934
2023
Q3 		$539K Hold
60,115
– – ﹤0.01% 2822
2023
Q2 		$742K Buy
60,115
+5,824
+11% +$62.3K ﹤0.01% 2786
2023
Q1 		$504K Buy
54,291
+5,252
+11% +$54.5K ﹤0.01% 2802
2022
Q4 		$515K Sell
49,039
-12,685
-21% -$161K ﹤0.01% 2878
2022
Q3 		$1.12M Buy
61,724
+497
+0.8% +$7.52K ﹤0.01% 2698
2022
Q2 		$868K Buy
+61,227
New +$1.01M ﹤0.01% 2851

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Nuveen's AURA Position: Q2 2026 in Review

Nuveen increased its Aura Biosciences (AURA) stake by 15% in Q2 2026, buying an estimated $79.4K and bringing the position to 83,804 shares worth $595K. The position accounts for ﹤0.01% of the portfolio, ranked #3189.

Nuveen first reported a position in AURA in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.12M in Q3 2022. 147 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Nuveen held 83,804 shares of Aura Biosciences worth $595K as of Q2 2026.
  • Nuveen bought 11,092 Aura Biosciences shares in Q2 2026, an estimated $79.4K.
  • Aura Biosciences made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3189 holding.
  • Nuveen first reported a position in Aura Biosciences in Q2 2022 and has held it in 17 quarters since.
  • Nuveen's Aura Biosciences position peaked at $1.12M in Q3 2022.
  • 147 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.